Narcolepsy beyond sleepiness : endocrine, metabolic and other aspects

The thesis contains a large study in which eight male hypocretin deficient narcolepsy with cataplexy patients and eight matched controls were enrolled. Blood was sampled before and on the 5th day of SXB administration. SXB was taken 2 times 3g per night for 5 consecutive nights. Both groups underwent 24-h blood sampling and many hormones (prolactin, Growth hormone, melatonin, ghrelin, leptin) were measured and compared before and during SXB treatment. A study using the golden standard on insuline sensitivity is decribed to compare insuline sensitivity between patients and controls, and between patients, before and during satisfactory SXB treatment. ANother study describes body and skintemperature differences between narcolepsy patients and controls. Another chapter describes a rarely described, common feature in narcolepsy, in which patients mistake the memory of a dream for a real experience. In another chapter describes that date of birth is not a risk factor for narcolepsy.SEIN, UCB Pharma, Koninklijke Auping, Wave Medical, Nederlandse vereniging voor Narcolepsie, Nederlandse vereniging voor slaap- en waak onderzoek, Heinen en Löwenstein, ChipsoftUBL - phd migration 201

Narcolepsy, driving and traffic safety

Driving performance in narcolepsy patients is often affected. This is predominantly caused by excessive daytime sleepiness and disturbed vigilance. To a lesser extent cataplexy and sleep paralysis may play a role as well. This chapter discusses experimental studies assessing driving performance in both treated and untreated patients with narcolepsy. Driving simulator studies, on-road tests in actual traffic, and psychological test batteries show that untreated narcolepsy may significantly impair driving ability and increase the risk of becoming involved in traffic accidents. However, much more research is needed to evaluate the effects of narcolepsy treatment on driving in normal traffic, and epidemiological data on traffic accident risks should be gathered. Relatively few studies have been performed to examine effects of narcolepsy treatment on driving ability. Up to now driving improvement has been demonstrated in patients who are successfully treated with methamphetamine and modafinil. Future driving studies should examine the effect of other treatment options

A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy

Paroxysmal Cerebral Disorder

Endocrine aspects of pharmacotherapy in narcolepsy

Paroxysmal Cerebral Disorder

Striking cessation of cataplexy by opioids

Paroxysmal Cerebral Disorder

Delusional Confusion of Dreaming and Reality in Narcolepsy

Paroxysmal Cerebral Disorder

Weight loss persists in narcolepsy patients using sodium oxybate

Paroxysmal Cerebral Disorder

Month of birth is not a risk factor for narcolepsy with cataplexy in the Netherlands.

Paroxysmal Cerebral Disorder